Pfizer says transparency in India’s drug regulatory process is improving


Meenakshi Nevatia, the country president and managing director of Pfizer India, remarked on the positive changes in India’s regulatory landscape for drug approval. She highlighted the increased transparency and systematization in the regulatory process, enabling pharmaceutical companies to introduce new drugs to the Indian market more quickly. Nevatia emphasized the alignment of this acceleration with India’s growing global connectivity, where doctors and patients have access to information about the latest developments in the medical field worldwide.

The Central Drugs Standard Control Organization (CDSCO) is actively exploring electronic submission processes to enhance further efficiency and transparency in bringing pharmaceutical products to the Indian market. This digital transformation aims to streamline and digitize the vast amount of data required for product approval, marking a significant step forward in the regulatory landscape.

Nevatia’s remarks at the PWC Pharma and Healthcare CEO Dialogues reflect the positive trajectory of the pharmaceutical industry in India. The changes in the drug launch process and regulatory transparency demonstrate a commitment to fostering a conducive environment for pharmaceutical companies to innovate and bring valuable medical solutions to the Indian population. The increased speed in introducing new drugs aligns with the country’s efforts to stay connected to global advancements in healthcare, benefiting both healthcare professionals and patients with access to the latest medical developments.